Spyre Therapeutics (SYRE) Receivables - Net (2015 - 2024)

Spyre Therapeutics (SYRE) posted Receivables - Net of $5.9 million for Q3 2024, little changed on a QoQ basis from $5.9 million in Q2 2024.

Spyre Therapeutics (SYRE) Receivables - Net (2015 - 2024) Analysis & Trends

Spyre Therapeutics' Receivables - Net history runs 6 years deep, the most recent figure standing at $5.9 million for Q3 2024.

Quarterly Receivables - Net changed N/A year-over-year to $5.9 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $5.9 million (changed N/A YoY) and the FY2017 annual result came in at $3.1 million, up 153.33% from the prior year.
Receivables - Net was $5.9 million for Q3 2024 at Spyre Therapeutics, roughly flat from $5.9 million in the prior quarter.
Across five years, Receivables - Net topped out at $21.5 million in Q1 2021 and bottomed at $5.9 million in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Spyre Therapeutics	257.83 Mn	257.83 Mn	-

Download Data